Irinotecan-Induced Acute toxicity, diarrhea, abdominal pain, abdominal cramping/discomfort, hypersalivation, nausea, vomiting, hyperlacrimation, hyperurination, miosis, bronchospasm, bronchorhea, cardiac arrhythmia, chest pain. Irinotecan, Acute toxicity, Predictive tool, Cholinergic toxicity, Pre-medication
Conditions
Interventions
Participants who received irinotecan treatment and experienced symptoms associated with cholinergic system activation comprise the group suffering irinotecan-induced acute toxicity. These symptoms may
Supportive Care,Supportive Care
Irinotecan-induced Toxicity Group,No Irinotecan-induced Toxicity Group
Sponsors
Payap University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years and older. 2. Diagnosed with cancer (ICD10: C00 to D49) and undergoing chemotherapy treatment at Nakornping Hospital between the years 2018-2024. 3. Received irinotecan medication at any dosage at least once.
Exclusion criteria
Exclusion criteria: 1. History of allergy or hypersensitivity to atropine. 2. Lack of recorded patient symptoms following chemotherapy treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute toxicity within 24 hours 24 hours after treatment Clinical observation | — |
Secondary
| Measure | Time frame |
|---|---|
| Completion of treatment course 6 months Medication record review | — |
Countries
Thailand
Contacts
Public ContactNatharin Phattayanon
Payap Iniversity
Outcome results
None listed